Anticholium Injection
NDC Package 81284-831-05

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Anticholium (physostigmine salicylate) injection is aNTICHOLIUM® is indicated for:1. This formulation utilizes a injection delivery system. Marketed by Provepharm Inc., this product is identified by NDC 81284-831.

Identification & Billing

NDC Package Code
81284-831-05
Package Description
5 AMPULE in 1 CARTON / 5 mL in 1 AMPULE
Product Code
81284-831
11-Digit Billing Format
81284083105
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Anticholium
Non-Proprietary Name
Physostigmine Salicylate
Substance Name
Physostigmine Salicylate
Dosage Form
Injection - A sterile preparation intended for parenteral use; five distinct classes of injections exist as defined by the USP.
Administration Route
Intravenous - Administration within or into a vein or veins.
Active Ingredient(s)
PHYSOSTIGMINE SALICYLATE .4 mg/mL
Usage Information
ANTICHOLIUM® is indicated for:1. the use as an antidote and/or antagonist in case of intoxication with and/or overdose of:alcoholtropane alkaloids (hyoscyamine, atropine, scopolamine, as e.g. in brugmansia, datura, atropa belladonna)amanita pantherina and amanita muscariatricyclic antidepressants (amitriptyline, imipramine, trimipramine, clomipramine, doxepine)antiemetics/antihistamines (phenothiazine, thioridazine, chlorpromazine, promethazine, diphenhydramine, dimenhydrinate)neuroleptic drugs (especially butyrophenones)benzodiazepinestolterodine, oxybutynineamantadine, diphenhydraminebaclofen4-hydroxybutyric acid (GHB)inhalation anestheticsketamine3-quinuclidinyl benzilate2. the treatment of postoperative disorders:Central anticholinergic syndrome (CAS)Delayed postoperative awakeningShivering

Regulatory & Marketing

Labeler Name
Provepharm Inc.
Product Type
Human Prescription Drug
Marketing Category
UNAPPROVED DRUG FOR USE IN DRUG SHORTAGE -
Start Marketing Date
10-05-2023
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 81284-831-05 identifies a specific commercial package of 5 ampule in 1 carton / 5 ml in 1 ampule of Anticholium, a human prescription drug labeled by Provepharm Inc.. This injection is formulated for intravenous use and contains physostigmine salicylate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Provepharm Inc. on October 05, 2023. The current certification is valid through December 31, 2026.

How is this Provepharm Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 81284083105. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
81284-831-05
11-Digit CMS (5-4-2)
81284-0831-05

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.